Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01723020 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

A Phase 1 study, sponsored by Kartos Therapeutics.

Completed
Registry status
Phase 1
Development phase
107
Enrollment target

NCT01723020: Completed Phase 1 study, sponsored by Kartos Therapeutics.

NCT01723020 is a Phase 1 study that has completed, run by Kartos Therapeutics. The registered enrollment target is 107 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01723020, a Phase 1 study, has completed, sponsored by Kartos Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
107 participants
Enrollment target

Study Summary

First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma

Primary Outcome

Subject incidence of adverse events, dose limiting toxicities, and clinically significant changes in vital signs, weight, ECGs and clinical laboratory tests

Interventions

  • DRUG AMG 232

Trial Details

FieldValue
Enrollment Target 107 participants
Start Date 2012-12-27
Est. Completion 2017-09-25
Phase Phase 1
Kartos Therapeutics

8 total trials

What the finished NCT01723020 record still lists

NCT01723020 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% higher).

The record links to 0 conditions, and to 1 intervention - of which AMG 232 is the first listed.

NCT01723020 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01723020 about?

NCT01723020 is a clinical study titled "A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma". First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma

What is the current status of trial NCT01723020?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 107 participants. The study started on 2012-12-27. Estimated completion is 2017-09-25.

What interventions are being tested in trial NCT01723020?

The interventions under investigation include: AMG 232 (DRUG).

Who is sponsoring clinical trial NCT01723020?

This trial is sponsored by Kartos Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01723020's enrollment target sits among peer trials

107 531st of 2000 higher than 1,470 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05491668 · 107 participants

    Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI

  • NCT06041594 · 107 participants · NA

    Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)

  • NCT06081426 · 107 participants · NA

    Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)

  • NCT06527599 · 107 participants · NA

    Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01723020, the US trial registry maintained by the National Library of Medicine. NCT01723020 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.